Zoetis Inc. (ZTS)
- Previous Close
161.69 - Open
161.41 - Bid 157.38 x 800
- Ask 160.98 x 800
- Day's Range
159.10 - 162.43 - 52 Week Range
139.70 - 200.33 - Volume
4,243,001 - Avg. Volume
3,269,695 - Market Cap (intraday)
70.908B - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
28.59 - EPS (TTM)
5.57 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield 2.00 (1.26%)
- Ex-Dividend Date Apr 21, 2025
- 1y Target Est
194.12
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
www.zoetis.com13,800
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ZTS
View More
Performance Overview: ZTS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZTS
View MoreValuation Measures
Market Cap
70.91B
Enterprise Value
75.94B
Trailing P/E
28.59
Forward P/E
25.77
PEG Ratio (5yr expected)
2.71
Price/Sales (ttm)
7.76
Price/Book (mrq)
15.23
Enterprise Value/Revenue
8.18
Enterprise Value/EBITDA
19.44
Financial Highlights
Profitability and Income Statement
Profit Margin
27.12%
Return on Assets (ttm)
15.11%
Return on Equity (ttm)
52.09%
Revenue (ttm)
9.29B
Net Income Avi to Common (ttm)
2.52B
Diluted EPS (ttm)
5.57
Balance Sheet and Cash Flow
Total Cash (mrq)
1.74B
Total Debt/Equity (mrq)
145.63%
Levered Free Cash Flow (ttm)
2.3B
Research Analysis: ZTS
View MoreResearch Reports: ZTS
View MoreZoetis Earnings: Solid Quarterly Organic Growth Comes With Potential Hints of Consumer Softness
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
RatingPrice TargetZoetis Earnings: Solid Quarterly Organic Growth Comes With Potential Hints of Consumer Softness
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
RatingPrice TargetZoetis Earnings: Leadership in Companion Animal Segment Supports Strong 2024 Results
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
RatingPrice TargetBUY as USDA approves bird flu vaccine for chickens
Zoetis Inc., a 2013 spinoff from Pfizer, focuses on the development, manufacture and commercialization of animal health vaccines and medicines, including parasiticides, anti-infectives, and medicated feed additives. The company develops products for both livestock and companion animals and distributes its products globally. Zoetis is a component of the S&P 500 and has roughly 13,800 employees.
RatingPrice Target